Gilead says Trodelvy improved overall survival in HR+/HER2- breast cancer
Justin Sullivan/Getty Images News


Gilead Sciences (NASDAQ:GILD) announced on Monday that its antibody-drug conjugate Trodelvy significantly improved overall survival in certain patients with HR+/HER2- metastatic breast cancer who took part in a Phase 3 trial.
The global TROPiCS-02 study was designed to evaluate Trodelvy against physiciansâ choice of chemotherapy in 543 HR+/HER2- breast cancer patients who had previously received endocrine therapy, CDK4/6 inhibitors, and two to four lines of chemotherapy for metastatic disease.

The second interim analysis of the randomized trial indicated a statistically significant and clinically meaningful benefit for overall survival, Gilead (GILD) said, adding that the detailed OS data would be shared at a future medical conference. 

Trodelvy is currently indicated for less common triple-negative breast cancer, and the company has filed a supplemental Biologics License Application (BLA) for the treatment in the U.S.
In March, Barclays questioned TROPiCS-02 data after the company said that the trial reached the primary endpoint for progression-free survival with statistical significance.

Gilead (GILD) added the drug as part of its $21B acquisition of Immunomedics in 2020.